An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target-Reference-Cited by-同舟云学术

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

Published:2017-10-11 Issue:411 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Mahil Satveer K.¹^ORCID,Catapano Marika¹²,Di Meglio Paola¹³^ORCID,Dand Nick¹^ORCID,Ahlfors Helena⁴,Carr Ian M.⁵^ORCID,Smith Catherine H.¹^ORCID,Trembath Richard C.¹^ORCID,Peakman Mark⁶^ORCID,Wright John⁷^ORCID,Ciccarelli Francesca D.²⁸^ORCID,Barker Jonathan N.¹,Capon Francesca¹^ORCID

Affiliation:

1. Division of Genetics and Molecular Medicine, King’s College London, London SE1 9RT, UK.

2. Cancer Systems Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK.

3. AhRimmunity Laboratory, Francis Crick Institute, London NW1 1AT, UK.

4. UCL Institute of Child Health, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK.

5. School of Medicine, University of Leeds, Leeds, LS9 7TF, UK.

6. Department of Immunobiology, King’s College London, London SE1 9RT, UK.

7. Bradford Royal Infirmary, Bradford Institute for Health Research, Bradford BD9 6RJ, UK.

8. Division of Cancer Studies, King’s College London, London SE1 1UL, UK.

Abstract

IL-36 receptor (IL-36R) blockade ameliorates psoriatic inflammation and should be well tolerated, because IL-36R knockout mutations are benign.

Funder

Wellcome Trust

Medical Research Council

Psoriasis Association

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference39 articles.

1. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions

2. Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

3. A. D. Burden B. Kirby Psoriasis and Related Disorders in Rook’s Textbook of Dermatology C. E. M. Griffiths J. N. Barker T. Bleiker R. J. Chalmers D. Creamer Eds. (Wiley-Blackwell 2016) chap. 35.

4. Immunology of Psoriasis

5. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal proteomics demonstrates Elafin as a psoriasis‐specific biomarker and highlights increased anti‐inflammatory activity around psoriatic plaques;Journal of the European Academy of Dermatology and Venereology;2024-08-19

2. NETs contribute to psoriasiform skin inflammation: A novel therapeutic approach targeting IL-36 cytokines by a small molecule tetrahydroxystilbene glucoside;Phytomedicine;2024-08

3. Cytokines in psoriasis: From pathogenesis to targeted therapy;Human Immunology;2024-07

4. Molecular aspects of Interleukin-36 cytokine activation and regulation;Biochemical Society Transactions;2024-06-28

5. Targeting the STAT3/IL-36G signaling pathway can be a promising approach to treat rosacea;Journal of Advanced Research;2024-06